Complications of HIV disease and antiretroviral therapy

Topics in Antiviral Medicine

Volumn 19, Issue 2, 2011, Pages 58-68

  Luetkemeyer, Anne F ^a   Havlir, Diane V ^b   Currier, Judith S ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SAN FRANCISCO GENERAL HOSPITAL   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

CONFERENCE PAPER; HEPATITIS C; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; METHODOLOGY; TIME;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; HEPATITIS C; HIV INFECTIONS; HUMANS; TIME FACTORS;

EID: 84855416550     PISSN: 21615861     EISSN: 21615853     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Chung RT. Acute hepatitis C virus infection. Clin Infect Dis. 2005;41(Suppl 1): S14-S17.
2. Grebely J, Petoumenos K, Hellard M, et al. Potential role for interleukin-28B genotype in treatment decision-making in recent hepatitis C virus infection. Hepatology. 2010;52:1216-1224.
3. Kim HN, Harrington RD, Crane HM, Dhanireddy S, Dellit TH, Spach DH. Hepatitis B vaccination in HIV-infected adults: current evidence, recommendations and practical considerations. Int J STD AIDS. 2009;20:595-600.
4. Fonseca MO, Pang LW, de Paula CN, Barone AA, Heloisa Lopes M. Randomized trial of recombinant hepatitis B vaccine in HIV-infected adult patients comparing a standard dose to a double dose. Vaccine. 2005;23:2902-2908.
5. Mestek M, Stauffer B, Westby C, et al. Endothelial fibrinolytic capacity is impaired in HIV-1-infected men. [Abstract 728.] 16th Conference on Retroviruses and Opportunistic Infections (CROI). February 8-11, 2009; Montreal, Canada.
6. Kuller LH, Tracy R, Belloso W, et al. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med. 2008;5:e203.
7. Grant RM, Lama JR, Anderson PL, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363:2587-2599.
8. Triant VA, Brown TT, Lee H, Grinspoon SK. Fracture prevalence among human immunodeficiency virus (HIV)-infected versus non-HIV-infected patients in a large U.S. healthcare system. J Clin Endocrinol Metab. 2008;93:3499-3504.
9. Institute of Medicine. Report: dietary reference intakes of calcium and vitamin D. November 30, 2010. http://www.iom. edu/Reports/2010/Dietary-Reference-Intakes-for-Calcium-and-Vitamin-D.aspx. Accessed April 15, 2011.
10. Kuk JL, Katzmarzyk PT, Nichaman MZ, Church TS, Blair SN, Ross R. Visceral fat is an independent predictor of all-cause mortality in men. Obesity (Silver Spring). 2006;14:336-341.
11. Daar ES, Tierney C, Fischl MA, et al. Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1: a randomized trial. Ann Intern Med. 2011;154:445-456.
12. Martinez E, Larrousse M, Llibre JM, et al. Substitution of raltegravir for ritonavirboosted protease inhibitors in HIV-infected patients: the SPIRAL study. AIDS. 2010;24:1697-1707.
13. Dubé MP, Komarow L, Mulligan K, et al. Long-term body fat outcomes in antiretroviral-naive participants randomized to nelfinavir or efavirenz or both plus dual nucleosides. Dual X-ray absorptiometry results from A5005s, a substudy of Adult Clinical Trials Group 384. JAIDS. 2007;45:508-514.
14. Tesoriero JM, Gieryic SM, Carrascal A, Lavigne HE. Smoking among HIV positive New Yorkers: prevalence, frequency, and opportunities for cessation. AIDS Behav. 2010;14:824-835.
15. Blanc FX, Sok T, Laureillard D, et al. Significant enhancement in survival with early (2 weeks) vs. late (8 weeks) initiation of highly active antiretroviral treatment (HAART) in severely immunosuppressed HIV-infected adults with newly diagnosed tuberculosis. [Abstract THLBB106.] 18th International AIDS Conference (IAC). July 18-23, 2010; Vienna, Austria.
16. Torok ME, Yen NTB, Chau TTH, et al. Randomized controlled trial of immediate versus deferred antiretroviral therapy in HIV-associated tuberculous meningitis. [Abstract H-1224.] 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). September 12-15, 2009, San Francisco, CA
17. Helb D, Jones M, Story E, et al. Rapid detection of Mycobacterium tuberculosis and rifampin resistance by use of on-demand, near-patient technology. J Clin Microbiol. 2010;48:229-237.
18. Boehme CC, Nabeta P, Hillemann D, et al. Rapid molecular detection of tuberculosis and rifampin resistance. N Engl J Med. 2010;363:1005-1015.
19. Kaplan JE, Benson C, Holmes KH, Brooks JT, Pau A, Masur H. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep. 2009;58:1-207.